Search

Your search keyword '"Graham, Barney S."' showing total 580 results

Search Constraints

Start Over You searched for: Author "Graham, Barney S." Remove constraint Author: "Graham, Barney S." Search Limiters Peer Reviewed Remove constraint Search Limiters: Peer Reviewed
580 results on '"Graham, Barney S."'

Search Results

1. Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine

2. Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials

3. Self-assembling SARS-CoV-2 spike-HBsAg nanoparticles elicit potent and durable neutralizing antibody responses via genetic delivery

4. Nanoparticle display of prefusion coronavirus spike elicits S1-focused cross-reactive antibody response against diverse coronavirus subgenera

7. Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidase

8. Antibody levels against respiratory syncytial virus fusion protein conformations and lack of association with life-threatening infection in previously healthy infants

10. Refined semi-lethal aerosol H5N1 influenza model in cynomolgus macaques for evaluation of medical countermeasures

11. Multivalent antigen display on nanoparticle immunogens increases B cell clonotype diversity and neutralization breadth to pneumoviruses

12. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape

13. Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial

14. Co-immunization with hemagglutinin stem immunogens elicits cross-group neutralizing antibodies and broad protection against influenza A viruses

15. Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial

17. Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial

18. A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination

21. Structure-based design of stabilized recombinant influenza neuraminidase tetramers

23. Stabilized coronavirus spike stem elicits a broadly protective antibody

24. Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial

26. mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates

28. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

29. Quadrivalent influenza nanoparticle vaccines induce broad protection

31. Severe Acute Respiratory Syndrome Coronavirus 2 Prevalence, Seroprevalence, and Exposure among Evacuees from Wuhan, China, 2020

32. Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk

33. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

34. Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial

35. Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial

38. Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial

40. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates

41. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials

42. Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses

43. Atomic structures of enterovirus D68 in complex with two monoclonal antibodies define distinct mechanisms of viral neutralization

44. A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone

45. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

46. Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial

47. Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection

Catalog

Books, media, physical & digital resources